Novel inactivating mutations of transforming growth factor-? type I receptor gene in head-and-neck cancer metastases

2001 ◽  
Vol 93 (5) ◽  
pp. 653-661 ◽  
Author(s):  
Taiping Chen ◽  
Wu Yan ◽  
Rebecca G. Wells ◽  
David L. Rimm ◽  
Jennifer McNiff ◽  
...  
Keyword(s):  
Head And Neck Cancer ◽  
Growth Factor ◽  
Head And Neck ◽  
Neck Cancer ◽  
Transforming Growth Factor ◽  
Receptor Gene ◽  
Type I ◽  
Cancer Metastases ◽  
Factor Type ◽  
Inactivating Mutations

scholarly journals TGF-Beta-Activated Cancer-Associated Fibroblasts Limit Cetuximab Efficacy in Preclinical Models of Head and Neck Cancer

Cancers ◽  
2020 ◽  
Vol 12 (2) ◽  
pp. 339 ◽  
Author(s):  
Ksenia M. Yegodayev ◽  
Ofra Novoplansky ◽  
Artemiy Golden ◽  
Manu Prasad ◽  
Liron Levin ◽  
...  
Keyword(s):  
Head And Neck Cancer ◽  
Growth Factor ◽  
Head And Neck ◽  
Neck Cancer ◽  
Stromal Cells ◽  
Transforming Growth Factor ◽  
Histopathological Analysis ◽  
Cancer Associated Fibroblasts ◽  
Tgf Beta ◽  
Stromal Compartment

Most head and neck cancer (HNC) patients are resistant to cetuximab, an antibody against the epidermal growth factor receptor. Such therapy resistance is known to be mediated, in part, by stromal cells surrounding the tumor cells; however, the mechanisms underlying such a resistance phenotype remain unclear. To identify the mechanisms of cetuximab resistance in an unbiased manner, RNA-sequencing (RNA-seq) of HNC patient-derived xenografts (PDXs) was performed. Comparing the gene expression of HNC-PDXs before and after treatment with cetuximab indicated that the transforming growth factor-beta (TGF-beta) signaling pathway was upregulated in the stromal cells of PDXs that progressed on cetuximab treatment (CetuximabProg-PDX). However, in PDXs that were extremely sensitive to cetuximab (CetuximabSen-PDX), the TGF-beta pathway was downregulated in the stromal compartment. Histopathological analysis of PDXs showed that TGF-beta-activation was detected in cancer-associated fibroblasts (CAFs) of CetuximabProg-PDX. These TGF-beta-activated CAFs were sufficient to limit cetuximab efficacy in vitro and in vivo. Moreover, blocking the TGF-beta pathway using the SMAD3 inhibitor, SIS3, enhanced cetuximab efficacy and prevented the progression of CetuximabProg-PDX. Altogether, our findings indicate that TGF-beta-activated CAFs play a role in limiting cetuximab efficacy in HNC.

Evaluation of incidence, significance, and prognostic role of circulating tumor microemboli and transforming growth factor-β receptor I in head and neck cancer

Head & Neck ◽  
2017 ◽  
Vol 39 (11) ◽  
pp. 2283-2292 ◽  
Author(s):  
Marcello Ferretti Fanelli ◽  
Thiago Bueno Oliveira ◽  
Alexcia Camila Braun ◽  
Marcelo Corassa ◽  
Emne Ali Abdallah ◽  
...  
Keyword(s):  
Head And Neck Cancer ◽  
Growth Factor ◽  
Head And Neck ◽  
Neck Cancer ◽  
Transforming Growth Factor ◽  
Transforming Growth Factor Β ◽  
Prognostic Role ◽  
Β Receptor ◽  
Circulating Tumor Microemboli

scholarly journals Attenuated Transforming Growth Factor β Signaling Promotes Nuclear Factor-κB Activation in Head and Neck Cancer

2009 ◽  
Vol 69 (8) ◽  
pp. 3415-3424 ◽  
Author(s):  
Jonah Cohen ◽  
Zhong Chen ◽  
Shi-Long Lu ◽  
Xin Ping Yang ◽  
Pattatheyil Arun ◽  
...  
Keyword(s):  
Head And Neck Cancer ◽  
Growth Factor ◽  
Head And Neck ◽  
Neck Cancer ◽  
Transforming Growth Factor ◽  
Transforming Growth Factor Β ◽  
Nuclear Factor Κb ◽  
Nuclear Factor

scholarly journals The Opioid Growth Factor (OGF)–OGF Receptor Axis Uses the p16 Pathway to Inhibit Head and Neck Cancer

2007 ◽  
Vol 67 (21) ◽  
pp. 10511-10518 ◽  
Author(s):  
Fan Cheng ◽  
Ian S. Zagon ◽  
Michael F. Verderame ◽  
Patricia J. McLaughlin
Keyword(s):  
Head And Neck Cancer ◽  
Growth Factor ◽  
Head And Neck ◽  
Neck Cancer ◽  
Opioid Growth Factor
Sign in / Sign up

Export Citation Format

Share Document